Taken together, our data suggest that the HDAC2 inhibitor enhances the antitumor effect of sunitinib through the HDAC2/YY1-YTHDC1 axis in ccRCC (Fig. 8L). The gene discussed is YTHDC1; the disease is nonpapillary renal cell carcinoma.